VetDC, a Colorado State University startup headquartered in Fort Collins, Colorado, focuses on in‑licensing, developing, and commercializing novel biotechnologies to address unmet medical needs in companion animals. Its lead candidate, VDC-1101, is a novel targeted agent that has demonstrated substantial antitumor activity in pet dogs with lymphoma. The company is advancing VDC-1101 toward veterinary approval and has initiated a manufacturing campaign supported by recent financing. VetDC completed a $1.5 million private financing to fund advancement and manufacturing of VDC-1101. Company leadership states that VDC-1101 is anticipated to be one of the first FDA‑approved drugs for the treatment of canine lymphoma. VetDC previously secured seed funding from the Colorado Institute for Drug, Device and Diagnostic Development (CID4) in 2011.

Total raised

$2M

Funding rounds

1

Latest round

Equity

Latest activity

Nov 2012